Quinolinic acid: a potent endogenous excitant at amino acid receptors in CNS
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Activation of the TRYCAT pathway diverts tryptophan metabolism away from serotonin synthesis, generating neurotoxic metabolites such as quinolinic acid that can overstimulate NMDA receptors and exacerbate mood dysregulation.
“Of note, activation of the TRYCAT pathway diverts tryptophan metabolism away from serotonin synthesis, generating neurotoxic metabolites such as quinolinic acid that can overstimulate N-methyl-D-aspartate (NMDA) receptors and exacerbate mood dysregulation (77).”
From Exploring the neurobiological markers of suicidal behaviors in pediatric population: a narrative review (2026) · cites this paper as [77]
Resulting cortisol dysregulation promotes microglial activation and elevated pro-inflammatory cytokines, particularly IL-6, which divert tryptophan metabolism toward neurotoxic kynurenine pathway products and away from serotonin synthesis.
“Resulting cortisol dysregulation promotes microglial activation and elevated pro-inflammatory cytokines, particularly IL-6, which divert tryptophan metabolism toward neurotoxic kynurenine pathway products and away from serotonin synthesis (77).”
From Exploring the neurobiological markers of suicidal behaviors in pediatric population: a narrative review (2026) · cites this paper as [77]
Cites
Phosphonate analogues of carboxylic acids as aminoacid antagonists on rat cortical neurones
Perkins, M., Stone, T. W., Collins, J. F., et al. (1981) · Neuroscience Letters · doi:10.1016/0304-3940(81)90021-5 · Cited by 133 · see citing works
Self-citationGlutamate as a Neurotransmitter
Mennerick, S. J., & Zorumski, C. F. (2001) · Encyclopedia of Life Sciences · doi:10.1038/npg.els.0000139 · Cited by 100 · see citing works
Pharmacology of receptors for excitatory amino acids
McLennan, H. (1989) · Drug Development Research · doi:10.1002/ddr.430170403 · Cited by 69 · see citing works
Biosynthesis in vitro of homarine and pyridine carboxylic acids in marine shrimp.
Netherton, J. C., & Gurin, S. (1980) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)43426-6 · Cited by 14 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
A Meta-Analysis of Cytokines in Major Depression
Dowlati, Y., Herrmann, N., Swardfager, W., Liu, H., Sham, L., Reim, E. K., & Lanctôt, K. L. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.09.033 · Cited by 4,729 · see citing works
Kynurenines in the mammalian brain: when physiology meets pathology
Schwarcz, R., Bruno, J. P., Muchowski, P. J., & Wu, H.-Q. (2012) · Nature Reviews Neuroscience · doi:10.1038/nrn3257 · Cited by 1,530 · see citing works
Berk, M., Kapczinski, F., Andreazza, A. C., Dean, O. M., Giorlando, F., Maes, M., Yücel, M., Gama, C. S., Dodd, S., Dean, B., et al. (2011) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2010.10.001 · Cited by 1,178 · see citing works
The secret life of NAD+: an old metabolite controlling new metabolic signaling pathways
Houtkooper, R. H., Cantó, C., Wanders, R. J., & Auwerx, J. (2010) · Endocrine Reviews · doi:10.1210/er.2009-0026 · Cited by 899 · see citing works
Kynurenine pathway metabolism and the microbiota-gut-brain axis
Kennedy, P. J., Cryan, J. F., Dinan, T. G., & Clarke, G. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.07.002 · Cited by 724 · see citing works
Maes, M., Leonard, B. E., Myint, A. M., Kubera, M., & Verkerk, R. (2011) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2010.12.017 · Cited by 700 · see citing works
Tryptophan metabolism in the central nervous system: medical implications
Ruddick, J. P., Evans, A. K., Nutt, D. J., Lightman, S. L., Rook, G. A. W., & Lowry, C. A. (2006) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399406000068 · Cited by 519 · see citing works
Quinolinic acid: an endogenous neurotoxin with multiple targets
Lugo-Huitrón, R., Ugalde Muñiz, P., Pineda, B., Pedraza-Chaverrí, J., Ríos, C., & Pérez-de la Cruz, V. (2013) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2013/104024 · Cited by 394 · see citing works
Lovelace, M. D., Varney, B., Sundaram, G., Lennon, M. J., Lim, C. K., Jacobs, K., Guillemin, G. J., & Brew, B. J. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.03.024 · Cited by 393 · see citing works
Interleukin-1β: A New Regulator of the Kynurenine Pathway Affecting Human Hippocampal Neurogenesis
Zunszain, P. A., Anacker, C., Cattaneo, A., Choudhury, S., Musaelyan, K., Myint, A. M., Thuret, S., Price, J., & Pariante, C. M. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2011.277 · Cited by 388 · see citing works
Oboh, G., Agunloye, O. M., Akinyemi, A. J., Ademiluyi, A. O., & Adefegha, S. A. (2013) · Neurochemical Research · doi:10.1007/s11064-012-0935-6 · Cited by 333 · see citing works
Bay-Richter, C., Linderholm, K. R., Lim, C. K., Samuelsson, M., Träskman-Bendz, L., Guillemin, G. J., Erhardt, S., & Brundin, L. (2015) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2014.07.012 · Cited by 304 · see citing works
The kynurenine pathway and neurodegenerative disease
Maddison, D. C., & Giorgini, F. (2015) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2015.03.002 · Cited by 309 · see citing works
Won, E., & Kim, Y.-K. (2016) · Current Neuropharmacology · doi:10.2174/1570159x14666151208113006 · Cited by 300 · see citing works
Obesity and cancer: existing and new hypotheses for a causal connection
Stone, T. W., McPherson, M., & Gail Darlington, L. (2018) · eBioMedicine · doi:10.1016/j.ebiom.2018.02.022 · Cited by 262 · see citing works
Self-citationBehan, W. M. H., McDonald, M., Darlington, L. G., & Stone, T. W. (1999) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0702940 · Cited by 225 · see citing works
Self-citationMithaiwala, M. N., Santana-Coelho, D., Porter, G. A., & O’Connor, J. C. (2021) · Cells · doi:10.3390/cells10061548 · Cited by 190 · see citing works
The role of depressive subtypes within the neuroinflammation hypothesis of major depressive disorder
Woelfer, M., Kasties, V., Kahlfuss, S., & Walter, M. (2019) · Neuroscience · doi:10.1016/j.neuroscience.2018.03.034 · Cited by 171 · see citing works
The kynurenine pathway and inflammation in amyotrophic lateral sclerosis
Chen, Y., Stankovic, R., Cullen, K. M., Meininger, V., Garner, B., Coggan, S., Grant, R., Brew, B. J., & Guillemin, G. J. (2010) · Neurotoxicity Research · doi:10.1007/s12640-009-9129-7 · Cited by 141 · see citing works
Strasser, B., Geiger, D., Schauer, M., Gostner, J., Gatterer, H., Burtscher, M., & Fuchs, D. (2016) · Nutrients · doi:10.3390/nu8110752 · Cited by 142 · see citing works
Parrott, J. M., Redus, L., & O’Connor, J. C. (2016) · Journal of Neuroinflammation · doi:10.1186/s12974-016-0590-y · Cited by 112 · see citing works
Role of glutamate receptors and glial cells in the pathophysiology of treatment-resistant depression
Kim, Y.-K., & Na, K.-S. (2016) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2016.03.009 · Cited by 84 · see citing works
Kynurenic Acid Levels are Increased in the CSF of Alzheimer’s Disease Patients
González-Sánchez, M., Jiménez, J., Narváez, A., Antequera, D., Llamas-Velasco, S., Martín, A. H.-S., Molina Arjona, J. A., López de Munain, A., Lleó Bisa, A., Marco, M.-P., et al. (2020) · Biomolecules · doi:10.3390/biom10040571 · Cited by 84 · see citing works
Kynurenic acid antagonists and kynurenine pathway inhibitors
Stone, T. W. (2001) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.10.4.633 · Cited by 79 · see citing works
Self-citationSen, Z. D., Danyeli, L. V., Woelfer, M., Lamers, F., Wagner, G., Sobanski, T., & Walter, M. (2021) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2020.12.020 · Cited by 65 · see citing works
The dose makes the poison: From glutamate-mediated neurogenesis to neuronal atrophy and depression
Rubio-Casillas, A., & Fernández-Guasti, A. (2016) · Reviews in the Neurosciences · doi:10.1515/revneuro-2015-0066 · Cited by 49 · see citing works
Gos, T., Myint, A.-M., Schiltz, K., Meyer-Lotz, G., Dobrowolny, H., Busse, S., Müller, U. J., Mawrin, C., Bernstein, H.-G., Bogerts, B., et al. (2014) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2014.05.012 · Cited by 49 · see citing works
Hormones, Metabolism and the Benefits of Exercise
(2017) · Research and Perspectives in Endocrine Interactions · doi:10.1007/978-3-319-72790-5 · Cited by 44 · see citing works
Atlas, A., Franzen-Röhl, E., Söderlund, J., Jönsson, E. G., Samuelsson, M., Schwieler, L., Sköldenberg, B., & Engberg, G. (2013) · International Journal of Tryptophan Research · doi:10.4137/ijtr.s13256 · Cited by 25 · see citing works
Khalil, O. S., Forrest, C. M., Pisar, M., Smith, R. A., Darlington, L. G., & Stone, T. W. (2013) · Immunopharmacology and Immunotoxicology · doi:10.3109/08923973.2013.828745 · Cited by 14 · see citing works
Self-citationSalehi, M., Saeidi, M., Amanat, M., Barias, T., Anyeji, U., Alzein, O., & Gunturu, S. (2026) · Frontiers in Pediatrics · doi:10.3389/fped.2026.1738009
“Of note, activation of the TRYCAT pathway diverts tryptophan metabolism away from serotonin synthesis, generating neurotoxic metabolites such as quinolinic acid that can overstimulate N-methyl-D-aspartate (NMDA) receptors and exacerbate mood dysregulation (77).”
- Authors
- Stone, T. W., & Perkins, M. N.
- Affiliations
- University of London (GB)
- ORCID
- Stone, T.W.
- Venue
- European Journal of Pharmacology
- Publisher
- Elsevier BV
- Published
- 1981-07
- Volume
- 72
- Issue
- 4
- Pages
- 411-412
- ISSN
- 0014-2999 (ISSN-L)
- OpenAlex
- W2075010970
- Cited by
- 751
- References
- 4
- Citations by year
- 2026: 12 · 2025: 12 · 2024: 23 · 2023: 29 · 2022: 27 · 2021: 27 · 2020: 22 · 2019: 16 · 2018: 17 · 2017: 15 · 2016: 26 · 2015: 27 · 2014: 16 · 2013: 23 · 2012: 22
- FWCI
- 8.91
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- European Journal of Pharmacology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Health Sciences › Medicine › Pharmacology › Treatment of Major Depression
- Keywords
- quinolinic acid, amino acid receptors, excitatory neurotransmission, central nervous system, major depressive disorder, inflammatory cytokines, glucocorticoids, corticotropin-releasing factor, network centrality, therapeutic target
- MeSH terms
- Action Potentials, Animals, Cerebral Cortex, Male, Pyridines, Quinolinic Acids, Receptors, Cell Surface, Quinolinic Acid, Receptors, Amino Acid, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review